Two phase 3 RCTs in adults with moderate-to-severe atopic dermatitis (1495 randomised): rocatinlimab beat placebo on week-24 EASI-75 (IGNITE 42% at 300 mg, 36% at 150 mg vs 13%; HORIZON 33% vs 14%). Pyrexia (12%) and chills were more common.
RCTn = 1,495
Guttman-Yassky et al. Efficacy and safety of rocatinlimab for the treatment of moderate-to-severe atopic dermatitis in ROCKET-IGNITE and ROCKET-HORIZON: two global, double-blind, placebo-controlled, randomised phase 3 clinical trials